100
Participants
Start Date
May 7, 2025
Primary Completion Date
December 13, 2028
Study Completion Date
December 13, 2028
TIVDAK
2 mg/kg once every 3 weeks (Q3W)
RECRUITING
University of Virginia Comprehensive Cancer Center, Charlottesville
RECRUITING
University of Virginia, Charlottesville
RECRUITING
UVA Health Cancer Care Pantops, Charlottesville
RECRUITING
Orlando Health Cancer Institute, Orlando
RECRUITING
Orlando Health Orlando Regional Medical Center, Orlando
RECRUITING
Orlando Health Winnie Palmer Hospital for Women & Babies, Orlando
RECRUITING
Broward Health North, Deerfield Beach
RECRUITING
Broward Health Coral Springs, Coral Springs
RECRUITING
HCA Mercy Hospital, Miami
RECRUITING
Mount Sinai Comprehensive Cancer Center, Miami Beach
RECRUITING
Mount Sinai Medical Center of Florida, Inc, Miami Beach
RECRUITING
Mount Sinai Comprehensive Cancer Center - Aventura, Aventura
RECRUITING
Broward Health Imperial Point, Fort Lauderdale
RECRUITING
Broward Health Medical Center, Fort Lauderdale
RECRUITING
Miami Valley Hospital South, Centerville
NOT_YET_RECRUITING
University Medical Center - New Orleans, New Orleans
RECRUITING
Trials365, LLC, Shreveport
RECRUITING
Willis Knighton Cancer Center, Shreveport
RECRUITING
Willis Knighton Physician Network - Hematology/Oncology, Shreveport
RECRUITING
Willis Knighton Physician Network/Gynecologic Oncology Associates, Shreveport
RECRUITING
WK Eye Institute North, Shreveport
RECRUITING
Willis Knighton Physician Network/Gynecologic Oncology Associates, Shreveport
RECRUITING
Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
RECRUITING
Women's Cancer Center of Nevada, Las Vegas
RECRUITING
Puerto Rico Cancer Specialists Clinical Trials, San Juan